Skip to main
HOTH

Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics (HOTH) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hoth Therapeutics is well-positioned for success due to its diverse pipeline of candidates targeting various medical needs, including cancer, Alzheimer's, and obesity. The company has also made significant progress in the development of its lead candidate, HT-001, as seen by its recent regulatory milestones and favorable pharmacokinetic profile. Additionally, the deployment of AI technology to support the development of HT-KIT highlights the company's commitment to utilizing innovative approaches to streamline its research and development process. However, as with any biopharmaceutical company, there are risks associated with clinical and regulatory processes and partnerships, which investors should be aware of. Overall, Hoth Therapeutics shows strong potential for growth and success, but caution should be taken when evaluating the company's risk factors.

Bears say

Hoth Therapeutics is making progress in developing treatments for cancer, skin toxicities, Alzheimer's, and obesity, but more controlled clinical evidence is needed to determine the commercial viability of their products. Additionally, upcoming milestones such as completing IND studies and potential partnerships may support the company's multi-program strategy, but further preclinical data and updates on development timelines will be key for investors to track. The company's strong collaborations and expanded intellectual property portfolio speak to their active operational activity, but investors should continue to monitor the company's progress before making investment decisions.

Hoth Therapeutics (HOTH) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hoth Therapeutics (HOTH) Forecast

Analysts have given Hoth Therapeutics (HOTH) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Hoth Therapeutics (HOTH) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hoth Therapeutics (HOTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.